PR PolyResearch

Join Free

NASDAQ

NextCure, Inc. (NXTC)

♥ 552 Thanks from members

NextCure, Inc. (NXTC) exhibits heavy bearish sentiment and legal scrutiny surrounding its proposed reverse merger with Avere Therapeutics, concurrent private financing up to $320M-$820M, and substantial going concern warnings as Q2 losses mount and legacy assets are relegated to contingent value rights.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Other Nasdaq Tickers

GraniteShares 2x Long AAPL Daily ETF (AAPB)

Apple Inc. (AAPL)

Direxion Daily AAPL Bear 1X ETF (AAPD)

Ascentage Pharma Group International - American Depository Shares (AAPG)

Direxion Daily AAPL Bull 2X ETF (AAPU)

Rocket Pharmaceuticals, Inc. - Warrant (RCKTW)